Literature DB >> 11079726

Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters.

H M Schuller1, B Porter, A Riechert.   

Abstract

OBJECTIVE: Lung cancer is the leading cause of cancer death in industrialized countries. Pulmonary adenocarcinoma (PAC) is the most common histologic type of lung cancer, and it is reproducibly induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK) in laboratory rodents. We have recently shown that the growth of cell lines derived from human PACs is controlled by beta-adrenergic receptors, and that NNK is a high affinity agonist for this receptor family.
DESIGN: In the current study, we have tested the relevance of these in in vitro findings for in vivo NNK-induced lung tumorigenesis, using a well-established hamster model of NNK-induced PAC.
RESULTS: Our experiments demonstrate a significant increase in NNK-induced PAC multiplicity in animals chronically exposed to the beta-adrenergic agonist epinephrine or theophylline which causes intracellular accumulation of the beta-adrenergic second messenger cAMP. On the other hand, our data show that administration of the beta-adrenergic antagonist propranolol prior to each NNK injection significantly inhibited the development of PACs. DISCUSSION: Our findings support the hypothesis that the development of tobacco-associated PAC may be modulated by beta-adrenergic agents, and that the interaction of NNK with beta-adrenergic receptors contributes to the genesis of this histologic lung cancer type.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079726     DOI: 10.1007/pl00008474

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  Role for catecholamines in tumor progression: possible use for β-blockers in the treatment of cancer.

Authors:  Eric V Yang
Journal:  Cancer Biol Ther       Date:  2010-07-06       Impact factor: 4.742

Review 2.  Sympathetic nervous system regulation of the tumour microenvironment.

Authors:  Steven W Cole; Archana S Nagaraja; Susan K Lutgendorf; Paige A Green; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2015-09       Impact factor: 60.716

Review 3.  Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?

Authors:  Hildegard M Schuller
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

4.  Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer.

Authors:  Hildegard M Schuller
Journal:  Transl Lung Cancer Res       Date:  2018-04

5.  Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei
Journal:  Curr Cancer Ther Rev       Date:  2012-05-01

6.  Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation.

Authors:  Jason W-L Eng; Chelsey B Reed; Kathleen M Kokolus; Rosemarie Pitoniak; Adam Utley; Mark J Bucsek; Wen Wee Ma; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Nat Commun       Date:  2015-03-10       Impact factor: 14.919

7.  The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors.

Authors:  Minoo D F Askari; Ming-Sound Tsao; Hildegard M Schuller
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 8.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

9.  Gamma-amino butyric acid (GABA) prevents the induction of nicotinic receptor-regulated signaling by chronic ethanol in pancreatic cancer cells and normal duct epithelia.

Authors:  Mohammed H Al-Wadei; Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-04

10.  GABA B receptor is a novel drug target for pancreatic cancer.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei; Mourad Majidi
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.